AstraZeneca wins early U.S. approval for blood cancer drug

LONDON (Reuters) - AstraZeneca has won U.S. approval for a new blood cancer drug several months earlier than expected, boosting its oncology portfolio - and requiring it to pay $1.5 billion to shareholders in the biotech company that first discovered the medicine.

Pfizer expects broad interest for consumer health business

NEW YORK (Reuters) - Pfizer Inc, the largest U.S. drugmaker, expects no shortage of suitors for its consumer health business and said it would decide whether to sell, spin off or retain the unit next year.

Where socioeconomic development lags, vision problems are more common

(Reuters Health) - Low levels of socioeconomic development are closely linked with a high burden of vision impairment, a recent study involving 190 countries and territories suggests.